GeneDx Holdings Corp. (NASDAQ:WGS) Receives $70.67 Consensus PT from Analysts

GeneDx Holdings Corp. (NASDAQ:WGS) has been assigned a consensus rating of “Moderate Buy” from the six brokerages that are presently covering the company, Marketbeat reports. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $70.67.

A number of equities research analysts have issued reports on WGS shares. Wells Fargo & Company upped their target price on GeneDx from $34.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 30th. The Goldman Sachs Group upped their price objective on shares of GeneDx from $54.00 to $70.00 and gave the stock a “neutral” rating in a report on Wednesday, October 30th. Craig Hallum boosted their target price on shares of GeneDx from $70.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. Finally, TD Cowen lifted their price objective on GeneDx from $75.00 to $118.00 and gave the stock a “buy” rating in a research note on Tuesday, January 7th.

Insider Buying and Selling at GeneDx

In related news, CEO Katherine Stueland sold 2,154 shares of the business’s stock in a transaction that occurred on Tuesday, October 29th. The shares were sold at an average price of $66.60, for a total transaction of $143,456.40. Following the completion of the sale, the chief executive officer now directly owns 105,426 shares of the company’s stock, valued at $7,021,371.60. The trade was a 2.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, major shareholder School Of Medicine At Mo Icahn sold 20,359 shares of the firm’s stock in a transaction on Friday, November 15th. The stock was sold at an average price of $69.78, for a total value of $1,420,651.02. Following the completion of the transaction, the insider now owns 2,846,474 shares in the company, valued at $198,626,955.72. This represents a 0.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,229,965 shares of company stock valued at $93,006,163. 27.30% of the stock is currently owned by company insiders.

Institutional Trading of GeneDx

A number of large investors have recently made changes to their positions in the company. MCF Advisors LLC raised its holdings in GeneDx by 107.7% during the fourth quarter. MCF Advisors LLC now owns 351 shares of the company’s stock worth $27,000 after acquiring an additional 182 shares in the last quarter. CWM LLC bought a new position in GeneDx during the third quarter worth about $89,000. Evolution Wealth Advisors LLC bought a new stake in GeneDx in the fourth quarter valued at approximately $202,000. PFG Investments LLC acquired a new stake in shares of GeneDx in the fourth quarter valued at approximately $252,000. Finally, SG Americas Securities LLC acquired a new position in shares of GeneDx during the 3rd quarter worth approximately $198,000. Institutional investors own 61.72% of the company’s stock.

GeneDx Stock Performance

Shares of WGS opened at $79.27 on Friday. The company’s 50 day moving average price is $77.89 and its 200 day moving average price is $56.81. The company has a market capitalization of $2.18 billion, a PE ratio of -25.49 and a beta of 2.02. GeneDx has a 52 week low of $2.85 and a 52 week high of $98.87. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.27 and a current ratio of 2.40.

GeneDx (NASDAQ:WGS) last posted its earnings results on Tuesday, October 29th. The company reported $0.04 EPS for the quarter, topping the consensus estimate of ($0.21) by $0.25. The company had revenue of $76.90 million during the quarter, compared to the consensus estimate of $64.98 million. GeneDx had a negative net margin of 31.25% and a negative return on equity of 13.35%. The company’s revenue for the quarter was up 44.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.82) earnings per share. Research analysts expect that GeneDx will post -0.24 EPS for the current fiscal year.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.